Tag: tildrakizumab
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
Sun Pharma inks deals with Hikma Pharma over distribution of psoriasis...
Sun Pharma and Hikma have entered into an exclusive licensing agreement for ILUMYA for the Middle East and North Africa regions...................
Sun Pharma achieves breaking results for its Psoriasis drug
The company has achieved primary end point in both Phase-3 studies in patients with moderate-to-severe plaque Psoriasis...
Spain’s Almirall to commercialize Sun Pharma’s Psoriasis drug in Europe
Under terms of the license agreement, the Spanish firm, Almirall will pay Sun Pharma an initial upfront payment of $50 million for.....